VK0RC1 Asp36Tyr warfarin resistance marker is common in Ethiopian individuals

Blood

Volumn 111, Issue 7, 2008, Pages 3903-3904

  Aklillu, Eleni ^a   Leong, Cheryl ^a   Loebstein, Ronen ^a   Halkin, Hillel ^a   Gak, Eva ^a  

^a SHEBA MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2C9; WARFARIN; ANTICOAGULANT AGENT; MENADIONE EPOXIDASE; MIXED FUNCTION OXIDASE;

AFRICAN AMERICAN; ANTICOAGULANT THERAPY; CHINESE; DRUG RESISTANCE; ETHIOPIA; GENE; GENETIC POLYMORPHISM; GENOTYPE; HEREDITY; HUMAN; INDIVIDUALIZATION; INTERINDIVIDUAL VARIABILITY; JAPANESE; JEW; LETTER; NEGRO; NUCLEOTIDE SEQUENCE; PHARMACOGENETICS; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; THROMBOSIS; VKORC1 GENE; ALLELE; AMINO ACID SUBSTITUTION; FEMALE; GENE FREQUENCY; GENETIC MARKER; GENETICS; MALE; MISSENSE MUTATION;

AFRICAN CONTINENTAL ANCESTRY GROUP; ALLELES; AMINO ACID SUBSTITUTION; ANTICOAGULANTS; DRUG RESISTANCE; ETHIOPIA; FEMALE; GENE FREQUENCY; GENETIC MARKERS; HUMANS; MALE; MIXED FUNCTION OXYGENASES; MUTATION, MISSENSE; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; WARFARIN;

EID: 43549104967     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-01-135863     Document Type: Letter

References (10)

1. Absher RK, Moore ME, Parker MH. Patient-specific factors predictive of warfarin dosage requirements. Ann Pharmacother. 2002;36:1512-1517.
2. Takahashi H, Wilkinson GR, Nutescu EA, et al. Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese. Caucasians and African-Americans. Pharmacogenet Genomics. 2006;16:101-110.
3. Loebstein R, Dvoskin I, Halkin H, et al. Acoding VKORC1 Asp36Tyr polymorphism predisposes to warfarin resistance. Blood. 2007;109:2477-2480.
4. Geisen C, Watzka M, Sittinger K, et al. VKORC1 haplotypes and their impact on the inter-individual and inter-ethnical variability of oral anticoagulation. Thromb Haemost. 2005:94:773-779.
5. Scordo G, Aklillu E, Yasar Ü, Dahl M, Spina E, Ingelman-Sundberg M. Genetic polymorphism of Cytochrome P450 2C9 in a Caucasian and a Black-African population. Br J Clin Pharmacol. 2001:52:447-450.
6. National Genter for Biotechnology Information. GenBank. http://www.ncbi.nlm.gov/sites/entrez. Accessed February 2008.
7. Gan GG, Teh A, Goh KY et al. Racial background is a determinant factor in the maintenance dosage of warfarin. Int J Hematol. 2003;78:84-86.
8. Kealey C, Chen Z, Christie J, et al. Warfarin and cytochrome P450 2C9 genotype: possible ethnic variation in warfarin sensitivity. Pharmacogenomics. 2007;8:217-225.
9. Schelleman H, Chen Z. Kealey C, et al. Warfarin response and vitamin K epoxide reductase complex 1 in African Americans and Caucasians. Clin Pharmacol Ther. 2007;81:742-747.
10. Kimmel SE, Christie J, Kealey C. et al. Apolipoprotein E genotype and warfarin dosing among Caucasians and African Americans. Pharmacogenomics J.2008:8:53-60.